Top Biotech Stock – StemCells Surges 14% as it Broadens Scope of Research on Human Neural Cells
StemCells Inc. (Nasdaq: STEM) increased 14% over the last two trading days as the company announced that it could initiate clinical trials of its HuCNS-SC purified human neural stem cells in chronic spinal cord injury patients already in 2011. This represents the third indication of HuCNS-SC cells after the infantile neuronal ceroid lipofuscinosis and Pelizeaus-Merzbacher Disease. STEM’s research and development - Continue Reading »
Pluristem Technologies wants to be your next Pharma stock
Continuing my series of reader/subscriber suggested emails, I bring you Pluristem Technologies (PSTI). I’m not sure that the guy who emailed me this one doesn’t work for the company or the IR firm. The email came right around the time that PSTI issued a flurry of press releases (Early July). I deliberately waited over a month just to see “where - Continue Reading »




